Available datapackage for study 'A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)'

The purpose of this study is to determine if the addition of apalutamide to ADT provides
superior efficacy in improving radiographic progression-free survival (rPFS) or overall
survival (OS) for participants with mHSPC.

本研究旨在明确，在雄激素剥夺疗法（ADT）基础上加用阿帕他胺（apalutamide），是否能为转移性去势敏感性前列腺癌（mHSPC）患者带来更优疗效，进而改善其影像学无进展生存期（rPFS）或总生存期（OS）。